Cosciens Biopharma (CSCI) confirmed that its board of directors has received a letter from Goodwood Fund and Puccetti Funds Management regarding six director nominations for the company’s upcoming annual and special meeting of shareholders. “We respectfully acknowledge receipt of the statement regarding the intentions from Goodwood and are carefully reviewing its contents,” said Ronnie Miller, Chair of the Board of Cosciens Biopharma. “With this in hand, the Board will evaluate and determine its path forward and remains fully committed to acting in the best interests of Cosciens and our shareholders.” The company will continue to provide updates to shareholders related to this matter, it added.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CSCI:
- COSCIENS Biopharma Receives Director Nominations from Goodwood
- COSCIENS Biopharma Reports Q1 2025 Results and Updates
- COSCIENS Biopharma Completes Merger with Ceapro and Restructures Governance
- COSCIENS Biopharma Reports Q1 2025 Results and Strategic Updates
- COSCIENS Biopharma Reports Q1 2025 Financial Results Amid Strategic Shifts